Bringing a new drug to market typically takes more than a decade and billions of dollars, and over 90% of candidates fail in clinical trials. Quantum computing infrastructure for drug discovery is emerging as one way to change those odds, though the real story is more measured than the headlines suggest.
Why Classical Tools Are Hitting a Wall
Computer-aided drug design relies on force-field approximations that struggle to capture polarization, charge transfer and electron correlation, the effects that govern how molecules recognize each other. Exact quantum-mechanical treatments scale exponentially on classical hardware, which makes them impractical for drug-sized molecules. Quantum computers represent molecular states more naturally, which is why researchers see a path past this accuracy-versus-scale trade-off.
Hybrid Workflows Are the Practical Model
The most realistic quantum computing infrastructure for drug discovery pairs quantum processors with classical systems. Quantum hardware handles a narrow, computationally intractable step, such as an active-site energy calculation, while classical systems manage everything else.
Pasqal and Qubit Pharmaceuticals show the approach in practice. Their hybrid method for protein hydration uses classical algorithms to generate water density data and quantum algorithms to place water molecules inside protein pockets, including hard-to-reach regions. Pasqal ran the algorithm on its neutral-atom machine, Orion, which it describes as a first for a molecular biology task of this importance.
Access: Cloud Platforms and On-Site Systems
Infrastructure is also about who can use the hardware. Most work runs through cloud services with metered billing, so medium-sized institutions and smaller companies can run pilot studies on pay-as-you-go plans instead of buying a machine. IBM Quantum, Amazon Braket, Microsoft Azure Quantum and Google Quantum AI all offer remote access to devices and simulators.
A few organizations host systems on-site. IBM Quantum System One installations operate at Cleveland Clinic, Rensselaer Polytechnic Institute and Yonsei University. The Cleveland Clinic and IBM system was billed as the first quantum computer dedicated to healthcare research.
Industry Is Already Building
Pharma has moved beyond curiosity:
- Boehringer Ingelheim is collaborating with Google Quantum AI.
- Bayer and Google are applying quantum chemistry to predict molecular properties.
- Pfizer and Gero are using hybrid quantum-classical architectures to find targets for fibrotic diseases.
- Roche’s pRED unit has explored quantum machine learning with QC Ware.
- AstraZeneca is working with IonQ through AWS and NVIDIA.
Algorithmiq has also developed hybrid algorithms designed for today’s noisy devices, showing that useful work doesn’t have to wait for fully fault-tolerant machines.
A Reality Check on Quantum Computing Infrastructure Drug Discovery
Progress here is real but early. One recent review stresses that no near-term hybrid workflow has solved an industrially relevant pharmaceutical problem. Published demonstrations still involve toy systems such as H2, LiH and BeH2. Several barriers remain:
- Hardware limits: Gate error rates and limited qubit scalability.
- Talent: A shortage of people with quantum expertise.
- Cost: System prices that shut out smaller players.
- Benchmarks: No standardized, community-scale tests on quantum hardware for drug design.
Accurate treatment of drug-sized systems will likely require fault-tolerant machines with millions of physical qubits, a target the same review places beyond 2030. The Pasqal and Qubit Pharmaceuticals collaboration, meanwhile, is not tied to any single hardware approach, and cloud access keeps the barrier to entry low.
What Comes Next
The strongest case for quantum computing infrastructure drug discovery today is modular integration. Quantum subroutines slot into proven classical workflows, targeting problems like metalloprotein active sites where classical methods fall short. Teams that build hybrid skills and cloud access now will be best placed when the hardware matures.
To join us in knowledge sharing, collaboration, and discussion around the challenges and opportunities shaping the future of laboratory innovation, meet with solution providers and hear talks from expert speakers, attend the Smart Labs Summit: Transforming Life Sciences R&D with Data, Technology & Automation, taking place October 20-21, 2026, in Barcelona, Spain.
For more information, click here or email us at info@innovatrix.eu for the event agenda. Visit our LinkedIn to stay up to date on our latest speaker announcements and event news.
